open access

Vol 64, No 1 (2014)
Research paper (original)
Published online: 2014-03-04
Get Citation

Stereotactic hypofractionated radiotherapy for prostate cancer patients — a preliminary report

Monika Rucińska, Marta Stefańczyk, Bartosz Kowalczuk, Joanna Minczewska, Sergiusz Nawrocki
DOI: 10.5603/NJO.2014.0003
·
Nowotwory. Journal of Oncology 2014;64(1):16-23.

open access

Vol 64, No 1 (2014)
Original article
Published online: 2014-03-04

Abstract

Background. Prostate cancer is the second most frequent malignancy in men in Poland. The standard treatment for early stage prostate cancer is operation and radiotherapy. The objective of the study was to investigate the effectiveness and safety of stereotactic radiotherapy for localized prostate cancer.

Material and methods. This is a prospective single-center clinical study. It was performed on prostate cancer patients with localized low- and intermediate-risk (according to NCCN) adenocarcinoma of the prostate T2-T3N0M0. Patients were prepared for treatment and immobilized according to a special protocol. For treatment planning CT and MRI scans were performed. IMRT plans were made. The PTV received 33.5 Gy in 5 fractions twice a week, which is equivalent to conventional 78 Gy in 39 fractions a 2 Gy (a/b for prostate cancer 1.4 Gy).

Results. in the analysis 32 patients were included. The tolerance of treatment was good and no Grade 3 or higher acute toxicity was reported (according to RTOG/EORTC). PSA levels systematically decreased (from a mean PSA level 10.46 before treatment to 0.37 ng/ml 12 months after the end of treatment.

Conclusions. Stereotactic hypofractionated radiotherapy for prostate cancer patients with X-rays from accelerator, with an IMRT technicque and very accurate patient positioning is an effective and safe treatment in the short-term analysis.

Abstract

Background. Prostate cancer is the second most frequent malignancy in men in Poland. The standard treatment for early stage prostate cancer is operation and radiotherapy. The objective of the study was to investigate the effectiveness and safety of stereotactic radiotherapy for localized prostate cancer.

Material and methods. This is a prospective single-center clinical study. It was performed on prostate cancer patients with localized low- and intermediate-risk (according to NCCN) adenocarcinoma of the prostate T2-T3N0M0. Patients were prepared for treatment and immobilized according to a special protocol. For treatment planning CT and MRI scans were performed. IMRT plans were made. The PTV received 33.5 Gy in 5 fractions twice a week, which is equivalent to conventional 78 Gy in 39 fractions a 2 Gy (a/b for prostate cancer 1.4 Gy).

Results. in the analysis 32 patients were included. The tolerance of treatment was good and no Grade 3 or higher acute toxicity was reported (according to RTOG/EORTC). PSA levels systematically decreased (from a mean PSA level 10.46 before treatment to 0.37 ng/ml 12 months after the end of treatment.

Conclusions. Stereotactic hypofractionated radiotherapy for prostate cancer patients with X-rays from accelerator, with an IMRT technicque and very accurate patient positioning is an effective and safe treatment in the short-term analysis.

Get Citation
About this article
Title

Stereotactic hypofractionated radiotherapy for prostate cancer patients — a preliminary report

Journal

Nowotwory. Journal of Oncology

Issue

Vol 64, No 1 (2014)

Article type

Research paper (original)

Pages

16-23

Published online

2014-03-04

DOI

10.5603/NJO.2014.0003

Bibliographic record

Nowotwory. Journal of Oncology 2014;64(1):16-23.

Authors

Monika Rucińska
Marta Stefańczyk
Bartosz Kowalczuk
Joanna Minczewska
Sergiusz Nawrocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl